You are not currently logged in.
Access JSTOR through your library or other institution:
The Theoretical Influence of Immunity between Strain Groups on the Progression of Drug-Resistant Tuberculosis Epidemics
Sanjay Basu, Evan Orenstein and Alison P. Galvani
The Journal of Infectious Diseases
Vol. 198, No. 10 (Nov. 15, 2008), pp. 1502-1513
Published by: Oxford University Press
Stable URL: http://www.jstor.org/stable/40254303
Page Count: 12
You can always find the topics here!Topics: Cross immunity, Mycobacterium tuberculosis, Tuberculosis, Immunity, Simulations, Infections, Disease risks, Disease models, HIV, Epidemiology
Were these topics helpful?See somethings inaccurate? Let us know!
Select the topics that are inaccurate.
Preview not available
Background. Emerging research suggests that genetically distinct strains of Mycobacterium tuberculosis may modulate the immune system differently. This may be of importance in high-burden settings where ≥1 genetic group of M. tuberculosis confers significant morbidity. Methods. A dynamic mathematical model was constructed to evaluate how different degrees of cross-immunity among M. tuberculosis groups could affect epidemics of drug-resistant tuberculosis (TB). Results. Simulated populations with immunogenically distinct TB strain groups experienced a heightened risk of drug-resistant TB, compared with populations without such strain diversity, even when the same rates of case detection and treatment success were achieved. The highest risks of infection were observed in populations in which HIV was prevalent. Drug-resistant strains with very low transmission fitness could still propagate in environments with reduced cross-immunity among different strain groups, even after common targets for case detection and treatment success are reached. Conclusions. It is possible that the propagation of drug-resistant strains could depend not only on the rate of development of resistance and the fitness of the drug-resistant strains but, also, on the diversity of the strains in the region. The risk of infection with drug-resistant strains could be amplified in locations where there is reduced crossimmunity between originating strain groups. This amplification may be most profound during the first few decades of TB treatment expansion.
The Journal of Infectious Diseases © 2008 Oxford University Press